Alector Inc. released a corporate presentation outlining its neuroscience pipeline and its Alector Brain Carrier (ABC) platform designed to enhance delivery of therapeutic cargos across the blood-brain barrier via transferrin receptor (TfR) targeting. The presentation highlights multiple ABC-enabled programs across antibodies, enzyme replacement therapy and siRNA, including AL101 (nivisnebart) for Alzheimer’s disease, AL137-ABC (anti-amyloid beta) for Alzheimer’s disease, AL050-ABC (GCase-ERT) for Parkinson’s disease, Gaucher disease and Lewy body dementia, and siRNA candidates targeting tau, alpha-synuclein and NLRP3. The company describes ABC optimization work focused on TfR epitope selection, affinity tuning across a wide range, and configuration testing across modalities, including non-human primate studies assessing brain uptake and hematologic measures. The presentation also summarizes the Phase 2 PROGRESS-AD study design for nivisnebart in early Alzheimer’s disease, including a 76-week treatment period and an interim futility analysis planned for the first half of 2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.